Intellectual Property India Publishes Patent Application for 'Bi Specific Anti-Muc16-Cd3 Antibodies And Anti-Muc16 Drug Conjugates' Filed by Regeneron Pharmaceuticals, Inc.

MUMBAI, India, Sept. 5 -- Intellectual Property India has published a patent application (202348053528 A) filed by Regeneron Pharmaceuticals, Inc., Tarrytown, U.S.A., on Aug. 9, 2023, for 'bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates.'

Inventor(s) include Haber, Lauric; Smith, Eric; Kelly, Marcus; Kirshner, Jessica R.; Coetzee, Sandra; Crawford, Alison; Nittoli, Thomas; and Liu, Yashu.

The application for the patent was published on Sept. 5, under issue no. 36/2025.

According to the abstract released by the Intellectual Property India: "Please refer to the attachment"

The patent application was internationally filed on Sept. 22, 2017, under International application No.PCT/US2017/053113.

Disclaimer: Curated by HT Syndication.